{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:58:15Z","timestamp":1786982295823,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K16179"],"award-info":[{"award-number":["17K16179"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s12185-024-03812-1","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T03:02:33Z","timestamp":1719889353000},"page":"325-336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comprehensive analysis of microRNAs modulated by histone deacetylase inhibitors identifies microRNA-7-5p with anti-myeloma effect"],"prefix":"10.1007","volume":"120","author":[{"given":"Masahiro","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3780-2993","authenticated-orcid":false,"given":"Sho","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Kuroki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Iwama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Kitadate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"3812_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410\u201327.","journal-title":"Lancet"},{"key":"3812_CR2","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","volume":"115","author":"I Hanamura","year":"2022","unstructured":"Hanamura I. Multiple myeloma with high-risk cytogenetics and its treatment approach. Int J Hematol. 2022;115:762\u201377.","journal-title":"Int J Hematol"},{"key":"3812_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1126\/science.272.5260.371","volume":"272","author":"AP Wolffe","year":"1996","unstructured":"Wolffe AP. Histone deacetylase: a regulator of transcription. Science. 1996;272:371\u20132.","journal-title":"Science"},{"key":"3812_CR4","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1365-2141.2009.07976.x","volume":"148","author":"EM Smith","year":"2010","unstructured":"Smith EM, Boyd K, Davies FE. The potential role of epigenetic therapy in multiple myeloma. Br J Haematol. 2010;148:702\u201313.","journal-title":"Br J Haematol"},{"key":"3812_CR5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.clml.2021.06.020","volume":"21","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Laubach JP, Richter J, et al. Panobinostat from bench to bedside: rethinking the treatment paradigm for multiple myeloma. Clin Lymphoma Myeloma Leuk. 2021;21:752\u201365.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3812_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s12185-016-2008-0","volume":"104","author":"T Harada","year":"2016","unstructured":"Harada T, Hideshima T, Anderson KC. Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. Int J Hematol. 2016;104:300\u20139.","journal-title":"Int J Hematol"},{"key":"3812_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-018-0119-y","volume":"8","author":"H Ohguchi","year":"2018","unstructured":"Ohguchi H, Hideshima T, Anderson KC. The biological significance of histone modifiers in multiple myeloma: clinical applications. Blood Cancer J. 2018;8:83.","journal-title":"Blood Cancer J"},{"key":"3812_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3390\/cancers11040475","volume":"11","author":"Y Imai","year":"2019","unstructured":"Imai Y, Hirano M, Kobayashi M, Futami M, Tojo A. HDAC inhibitors exert anti-myeloma effects through multiple modes of action. Cancers (Basel). 2019;11:475.","journal-title":"Cancers (Basel)"},{"key":"3812_CR9","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1200\/JCO.2012.46.7068","volume":"31","author":"JF San-Miguel","year":"2013","unstructured":"San-Miguel JF, Richardson PG, G\u00fcnther A, et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013;31:3696\u2013703.","journal-title":"J Clin Oncol"},{"key":"3812_CR10","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2013-01-481325","volume":"122","author":"PG Richardson","year":"2013","unstructured":"Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013;122:2331\u20137.","journal-title":"Blood"},{"key":"3812_CR11","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195\u2013206.","journal-title":"Lancet Oncol"},{"key":"3812_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","volume":"109","author":"M Duvic","year":"2007","unstructured":"Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31\u20139.","journal-title":"Blood"},{"key":"3812_CR13","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","volume":"28","author":"SJ Whittaker","year":"2010","unstructured":"Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485\u201391.","journal-title":"J Clin Oncol"},{"key":"3812_CR14","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1111\/cas.15431","volume":"113","author":"A Utsunomiya","year":"2022","unstructured":"Utsunomiya A, Izutsu K, Jo T, Yoshida S, et al. Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia\/lymphoma: phase IIb results. Cancer Sci. 2022;113:2778\u201387.","journal-title":"Cancer Sci"},{"key":"3812_CR15","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2022.280996","volume":"108","author":"S Rai","year":"2023","unstructured":"Rai S, Kim WS, Ando K, et al. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica. 2023;108:811\u201321.","journal-title":"Haematologica"},{"key":"3812_CR16","doi-asserted-by":"publisher","first-page":"7572","DOI":"10.18632\/oncotarget.13810","volume":"8","author":"F Abe","year":"2017","unstructured":"Abe F, Kitadate A, Ikeda S, et al. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma. Oncotarget. 2017;8:7572\u201385.","journal-title":"Oncotarget"},{"key":"3812_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","volume":"173","author":"DP Bartel","year":"2018","unstructured":"Bartel DP. Metazoan MicroRNAs. Cell. 2018;173:20\u201351.","journal-title":"Cell"},{"key":"3812_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203\u201322.","journal-title":"Nat Rev Drug Discov"},{"key":"3812_CR19","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1158\/1535-7163.MCT-15-0985","volume":"15","author":"N Amodio","year":"2016","unstructured":"Amodio N, Stamato MA, Gull\u00e0 AM, et al. Therapeutic targeting of miR-29b\/HDAC4 epigenetic loop in multiple myeloma. Mol Cancer Ther. 2016;15:1364\u201375.","journal-title":"Mol Cancer Ther"},{"key":"3812_CR20","doi-asserted-by":"publisher","first-page":"12885","DOI":"10.1073\/pnas.0806202105","volume":"105","author":"F Pichiorri","year":"2008","unstructured":"Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 2008;105:12885\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3812_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1745-6150-6-23","volume":"6","author":"J Chi","year":"2011","unstructured":"Chi J, Ballabio E, Chen XH, et al. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct. 2011;6:23.","journal-title":"Biol Direct"},{"key":"3812_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/ng.2007.30","volume":"40","author":"TC Chang","year":"2008","unstructured":"Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008;40:43\u201350.","journal-title":"Nat Genet"},{"key":"3812_CR23","doi-asserted-by":"publisher","first-page":"8822","DOI":"10.1158\/0008-5472.CAN-10-0638","volume":"70","author":"YT Chou","year":"2010","unstructured":"Chou YT, Lin HH, Lien YC, et al. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras\/ERK\/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res. 2010;70:8822\u201331.","journal-title":"Cancer Res"},{"key":"3812_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103950","volume":"78","author":"Z Yu","year":"2022","unstructured":"Yu Z, Wei X, Liu L, et al. Indirubin-3\u2019-monoxime acts as proteasome inhibitor: therapeutic application in multiple myeloma. EBioMedicine. 2022;78: 103950.","journal-title":"EBioMedicine"},{"key":"3812_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065671","volume":"8","author":"N Sanchez","year":"2013","unstructured":"Sanchez N, Gallagher M, Lao N, et al. MiR-7 triggers cell cycle arrest at the G1\/S transition by targeting multiple genes including Skp2 and Psme3. PLoS\u00a0One. 2013;8: e65671.","journal-title":"PLoS\u00a0One"},{"key":"3812_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/bjc.2013.728","volume":"110","author":"S Xiong","year":"2014","unstructured":"Xiong S, Zheng Y, Jiang P, et al. PA28gamma emerges as a novel functional target of tumour suppressor microRNA-7 in non-small-cell lung cancer. Br J Cancer. 2014;110:353\u201362.","journal-title":"Br J Cancer"},{"key":"3812_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.yexcr.2018.01.005","volume":"363","author":"S Tang","year":"2018","unstructured":"Tang S, Ma D, Cheng B, et al. Crucial role of HO-1\/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma. Exp Cell Res. 2018;363:196\u2013207.","journal-title":"Exp Cell Res"},{"key":"3812_CR28","doi-asserted-by":"publisher","first-page":"9709","DOI":"10.1002\/cam4.5679","volume":"12","author":"K Abe","year":"2023","unstructured":"Abe K, Ikeda S, Nara M, et al. Hypoxia-induced oxidative stress promotes therapy resistance via upregulation of heme oxygenase-1 in multiple myeloma. Cancer Med. 2023;12:9709\u201322.","journal-title":"Cancer Med"},{"key":"3812_CR29","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.3390\/cancers11111738","volume":"11","author":"H Handa","year":"2019","unstructured":"Handa H, Murakami Y, Ishihara R, Kimura-Masuda K, Masuda Y. The role and function of microRNA in the pathogenesis of multiple myeloma. Cancers (Basel). 2019;11:1738.","journal-title":"Cancers (Basel)"},{"key":"3812_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12935-015-0259-0","volume":"15","author":"J Zhao","year":"2015","unstructured":"Zhao J, Tao Y, Zhou Y, et al. MicroRNA-7: a promising new target in cancer therapy. Cancer Cell Int. 2015;15:103.","journal-title":"Cancer Cell Int"},{"key":"3812_CR31","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1158\/0008-5472.CAN-12-2037","volume":"73","author":"H Okuda","year":"2013","unstructured":"Okuda H, Xing F, Pandey PR, et al. miR-7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4. Cancer Res. 2013;73:1434\u201344.","journal-title":"Cancer Res"},{"key":"3812_CR32","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/carcin\/bgu242","volume":"36","author":"T Suto","year":"2015","unstructured":"Suto T, Yokobori T, Yajima R, et al. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis. 2015;36:338\u201345.","journal-title":"Carcinogenesis"},{"key":"3812_CR33","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/cas.13183","volume":"108","author":"S Ikeda","year":"2017","unstructured":"Ikeda S, Kitadate A, Abe F, et al. Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma. Cancer Sci. 2017;108:641\u201352.","journal-title":"Cancer Sci"},{"key":"3812_CR34","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1128\/MCB.00853-12","volume":"33","author":"WJ Wong","year":"2013","unstructured":"Wong WJ, Qiu B, Nakazawa MS, Qing G, Simon MC. MYC degradation under low O2 tension promotes survival by evading hypoxia-induced cell death. Mol Cell Biol. 2013;33:3494\u2013504.","journal-title":"Mol Cell Biol"},{"key":"3812_CR35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ccr.2005.08.005","volume":"8","author":"CV Dang","year":"2005","unstructured":"Dang CV, O\u2019donnell KA, Juopperi T. The great MYC escape in tumorigenesis. Cancer Cell. 2005;8:177\u20138.","journal-title":"Cancer Cell"},{"key":"3812_CR36","doi-asserted-by":"publisher","first-page":"6462","DOI":"10.1038\/onc.2008.312","volume":"27","author":"B Hoffman","year":"2008","unstructured":"Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene. 2008;27:6462\u201372.","journal-title":"Oncogene"},{"key":"3812_CR37","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/s41556-019-0408-0","volume":"21","author":"S Schmidt","year":"2019","unstructured":"Schmidt S, et al. A MYC-GCN2-eIF2\u03b1 negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer. Nat Cell Biol. 2019;21:1413\u201324.","journal-title":"Nat Cell Biol"},{"key":"3812_CR38","doi-asserted-by":"publisher","first-page":"13079","DOI":"10.1038\/s41598-020-70157-0","volume":"10","author":"S Liu","year":"2020","unstructured":"Liu S, Zang H, Zheng H, et al. miR-4634 augments the anti-tumor effects of RAD001 and associates well with clinical prognosis of non-small cell lung cancer. Sci Rep. 2020;10:13079.","journal-title":"Sci Rep"},{"key":"3812_CR39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41419-022-04565-7","volume":"13","author":"S Liu","year":"2022","unstructured":"Liu S, Wang W, Ning Y, et al. Exosome-mediated miR-7-5p delivery enhances the anticancer effect of Everolimus via blocking MNK\/eIF4E axis in non-small cell lung cancer. Cell Death Dis. 2022;13:129.","journal-title":"Cell Death Dis"},{"key":"3812_CR40","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s12185-023-03706-8","volume":"119","author":"T Maruhashi","year":"2024","unstructured":"Maruhashi T, Miki H, Sogabe K, et al. Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib. Int J Hematol. 2024;119:291\u2013302.","journal-title":"Int J Hematol"},{"key":"3812_CR41","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12185-023-03705-9","volume":"119","author":"K Sogabe","year":"2024","unstructured":"Sogabe K, Nakamura S, Higa Y, et al. Acute accumulation of PIM2 and NRF2 and recovery of \u03b25 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors. Int J Hematol. 2024;119:303\u201315.","journal-title":"Int J Hematol"},{"key":"3812_CR42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.canlet.2016.08.018","volume":"386","author":"J Guo","year":"2017","unstructured":"Guo J, Hao J, Jiang H, et al. Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Myc-glycolysis signaling axis. Cancer Lett. 2017;386:161\u20137.","journal-title":"Cancer Lett"},{"key":"3812_CR43","doi-asserted-by":"publisher","first-page":"1761205","DOI":"10.1080\/2162402X.2020.1761205","volume":"9","author":"M Boulpicante","year":"2020","unstructured":"Boulpicante M, Darrigrand R, Pierson A, et al. Tumors escape immunosurveillance by overexpressing the proteasome activator PSME3. Oncoimmunology. 2020;9:1761205.","journal-title":"Oncoimmunology"},{"key":"3812_CR44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.yexcr.2017.05.017","volume":"358","author":"Z Yi","year":"2017","unstructured":"Yi Z, Yang D, Liao X, et al. PSME3 induces epithelial-mesenchymal transition with inducing the expression of CSC markers and immunosuppression in breast cancer. Exp Cell Res. 2017;358:87\u201393.","journal-title":"Exp Cell Res"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03812-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03812-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03812-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T07:30:46Z","timestamp":1724916646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03812-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["3812"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03812-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"8 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sho Ikeda: Honoraria, Janssen Pharma, Akihiro Kitadate: Honoraria, Janssen Pharma and Sanofi, Naoto Takahashi: Honoraria, Novartis Pharma; Research funding, Takeda Pharmaceutical Company, Kyowa Hakko Kirin, and Novartis Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}